Several small molecule activators, which induce the tetramerization of PKM2 (activation), have been developed and have shown promising results in blocking glycolysis and inhibiting tumor cell proliferation [12,13,14], including TEPP-46, 6-((3-aminophenyl)methyl)-4-methyl-2-methylsulfinylthieno[3,4]pyrrolo[1,3-d]pyridazin-5-one [13,14,15]. The gene discussed is PKM; the disease is neoplasm.